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Abstract
Background: HIV clinical presentation in the acute stage is variable and some of its virological and immunological
aspects are not completely understood. Most cases of HIV- associated reactive hemophagocytic syndrome have
been reported in patients with advanced stages of HIV and to our knowledge, there are only 8 cases in the English
literature presenting during acute HIV infection, most in East Asia, being this the first case in a European patient.
Case presentation: We report a case of a European Caucasian 27- year old woman with a primary HIV- infection
presenting with extremely low CD4+ T cell count who developed a haemophagocytic syndrome after starting ART
and in whom we documented a very unusual serological and virological response, characterized by an impaired
HIV- antibody production and a 12 month time frame to reach an undetectable viral load, despite no evidence of
resistance.
Conclusions: This case report apart from describing an unusual clinical presentation of an acute HIV infection as
hemophagocytic syndrome provides useful information that might contribute for understanding some subtle issues
in acute HIV infection, namely the dynamics of virological and immunological aspects after antiretroviral therapy
initiation.
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Background
Acute Human Immunodeficiency Virus (HIV) infection
clinical presentation is variable and some of its viro-
logical and immunological aspects are not completely
understood.
We report a case of a woman with a primary HIV- in-
fection who developed a hemophagocytic syndrome and
in whom we documented a very unusual serological and
virological response, characterized by an impaired HIV-
antibody production and a 12 month time frame to
reach an undetectable viral load.
Case presentation
A 27 year old female, presented to our hospital on 5th
July 2013 with fever, throat pain, non productive cough,
anorexia and weight loss (4 kg) for one month duration.
The patient recalled unprotected sexual intercourse
with a steady partner 2 months before symptoms pres-
entation. There was no history of intravenous drug use,
blood transfusions or past surgical procedures. She had
performed a mandatory HIV test before her departure
from Eastern Europe, in August 2012, which was
negative.
On admission the patient vital signs were: temperature
of 39, 5 °C, blood pressure 110/65 mmHg, pulse rate 102
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beats per minute and respiratory rate 16 breaths per
minute.
White exudates were evident in oropharyngeal exam-
ination. Neither rash nor palpable cervical, axillary or in-
guinal lymph nodes were present.
Routine laboratory revealed pancytopenia: Hemoglobin
(Hb) was 7, 9 g/dL, White blood cells (WBC) was 1.72 ×
109/L with 0.79 × 109/L neutrophils, 0.40 × 109/L lym-
phocytes and 88 × 109/L platelets.
C-reactive protein (CRP) was 0, 6 mg/L (normal range
< 3 mg/L). Renal function and liver tests were normal.
HIV screening was positive and the immunoblot assay-
INNO-LIA™ indeterminate. An additional file describes
the tests in more detail [See Additional file 1].
She was admitted to the Infectious Diseases Department
with the presumed diagnosis of an acute HIV-infection.
RNA viral load in plasma was of 384.687 cp/mL (5, 59 log
10), CD4+ cell count was 13/mm3. A type 1, subtype A
HIV virus was identified (Fig. 1).
At admission: blood cultures were sterile; Monospot test
negative. Serological studies revealed: IgG positive with
IgM negative for Epstein barr Virus (EBV), Toxoplasma
gondii, Cytomegalovirus (CMV) and Herpes simplex 1; IgG
and IgM were negative for Herpes simplex 2. Treponema
pallidum particle agglutination assay, cryptococcal antigen,
CMV antigen and CMV viral load in blood also negative.
Chest X-Ray, abdominal ultrasound, chest and abdom-
inal CT scan did not reveal relevant abnormality.
Antiretroviral therapy (ART) was started on 11th July
with tenofovir/emtricitabine and atazanavir/ritonavir.
The patient maintained fever but had no focal
symptoms.
Asymptomatic progressive liver enzymes elevation
was documented (aspartate aminotransferase/alanine
aminotransferase (AST/ALT): 153/80UI/L; alkaline
phosphatase (ALK) 321UI/L, total bilirubin 3.89 mg/dL).
The results of genotypic resistance test became avail-
able and revealed no significant mutations that could
confer resistance either to protease or reverse transcript-
ase inhibitors.
At 7th day ritonavir was/ritonavir was switched to ral-
tegravir (Fig. 1). Despite this, liver cytolysis/cholestasis
continued worsening (Fig. 2) and was accompanied by
aggravated pancytopenia.
Lactate dehydrogenase (LDH) and Beta-2 microglobu-
lin were elevated: 1872 mg/dL (Normal <225 mg/dL)
and 4750 mg/dL (Normal < 2530 mg/dL), respectively.
Ferritin was of 2095 ng/ml (Normal: 10–120 ng/mL),
triglycerides was of 254 mg/dL (Normal < 150 mg/dL).
Fibrinogen was diminished (1, 14 g/L), as NK activity (0,
09 %).
Bone marrow histological examination (18th July) re-
vealed: hypercelularity and architectural disorganization,
erythroid hyperplasia with dyserythropoiesis, lymphoid
aggregates, perivascular and intersticial plasmocytosis
and activated macrophages engulfing erythrocytes. No
evidence of mycobacteria or CMV infection was present
(both excluded by cultural exam and polymerase chain
reaction (PCR)) (Fig. 3).
Liver biopsy (25th July) revealed: portal inflammatory
infiltrates, disperse necroinflammatory lesions, moderate
cholestasis, hepatocyte ballooning and multifocal esteatosis.
At this stage, a diagnosis of Hemophagocytic Syn-
drome was assumed, according to the Haemophagocytic
Histiolymphocytosis (HLH) -2004 criteria. Repeated
blood cultures (including for mycobacterium), crypto-
coccal antigen, CMV PCR and antigen and EBV PCR
were negative. CRP was within normal range along this
Fig. 1 CD4 count and HIV viral load dynamics over 12 months after HIV diagnosis and ART initiation
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period. ART was maintained and steroids were started
(prednisolone 80 mg/day).
At four weeks of therapy, viral load had not declined
significantly (Fig. 1). At this point, genotypic drug resist-
ance test was repeated and again no relevant mutations
were identified.
At 5 weeks of therapy, fever and asthenia persisted
with no other symptoms.
At 6th week viral load increased to 268.211cp/mL
(Fig. 1). Esophageal candidiasis and cytomegalic reactiva-
tion without organ involvement were documented and
treated.
A group decision was to optimize ART to tenofovir/
emtricitabine + darunavir/ ritonavir + etravirine (TDF/
FTC + DRV/r + ETV) (Fig. 1). The patient was on Daily
Observed Therapy.
A third genotypic resistance test was performed and
again no relevant or new mutations were found, using
different interpretation algorithms: Stanford HIVdb and
HIV REGA algorithms (version 8.0.2; available at http://
www.rega.kuleuven.be/cev/). An additional file describes
this in more detail [See Additional file 2].
INNO-LIA™ HIV I/II test was repeated and an indeter-
minate result was obtained once again with the same re-
activity rating for gp41.
Patient’s condition progressively improved, apyrexia
was documented and she was discharged, with a pro-
gressively reducing doses of steroids, by 20th of Septem-
ber (after ~11 weeks of hospital stay; ~ 9 weeks of FTC/
TDF + ETV +DRV/r).
Subsequent viral load quantifications revealed no sig-
nificant decline (Fig. 1).
Given this unexpected response to therapy a blood sam-
ple was sent to Monogram Biosciences® (San Francisco,
USA), for phenotypic and genotypic resistance testing: the
virus was sensitive to all Nucleoside and Non-Nucleoside
Reverse Transcriptase Inhibitors (NRTIs/NNRTIs) and PI
drugs. An additional file describes this in more detail [See
Additional file 3].
Therapeutic drug monitoring (TDM) was also per-
formed and TDF/FTC +DRV/r + ETV were in thera-
peutic levels.
Three plasma samples from different dates (August,
September and November 2013) were sent to INNOGE-
NETICS reference laboratory in Belgium for HIV testing
confirming the INNO-LIA HIV Score results of our in-
stitution. Based on those results, they concluded that
this patient was not developing expected antibody
Fig. 2 Liver enzymes evolution
Fig. 3 Bone Marrow Biopsy: activated macrophages engulfing
erythrocytes suggesting HS
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reactivity. An additional file describes this in more detail
[See Additional file 4].
Determination of specific antibodies against Pneumo-
coccal capsule polysaccharides and tetanus toxoid were
also performed and results were below reference values.
Hepatitis B surface antibody (HBsAb), after 2 doses of
hepatitis B vaccine, was non quantifiable.
Almost a year after HIV diagnosis and ART initiation,
HIV viral load was of 70cp/mL (1, 85 Log10) and CD4+
count of 376/mm3 (04/06/2014). ART was maintained
(Fig. 1).
In July 2014, the patient returned to her country and
given the unavailability of the current regimen in her
homeland, ART was switched to tenofovir/emtricitabine
+ efavirenz. Patient remained asymptomatic and in the
last determination dating of 14th July 2014 HIV blood
viral load was not detectable (<20cp/mL as threshold)
and CD4+ cell count was of 312/mm3.
Conclusions
We report a case of an acute HIV infection with a rare
and intriguing clinical, virological and serological
behaviour.
Considering the potential benefits of early treatment
[1–3], ART was started, with a PI based regimen while
waiting for genotypic resistance test results. Despite this,
patient condition got worse and clinical, analytical and
histological findings were consistent with the diagnosis
of hemophagocytic syndrome [4, 5]. This is itself a rare
condition during acute HIV infection [6–8].
Whether hemophagocytic syndrome in this case is at-
tributable to HIV itself, to ART, to an immune reconsti-
tution syndrome (IRIS) or other cause, is a matter of
interesting debate.
In our patient hemophagocytic syndrome was diag-
nosed early after ART introduction, persisted after chan-
ging the drug regimen and despite the absence of
virological and immune response to therapy, all facts
that argue against ART or IRIS as causes. Other possible
precipitating factors such as latent virus reactivation
were also excluded at that stage. For us the most likely
explanation is that hemophagocytic syndrome was a
manifestation of the complex inflammatory storm occur-
ring in acute HIV infection. Although we have started
steroids (80 mg/daily) soon after the diagnosis, the re-
sponse to this therapy was slow. As in other secondary
Hemophagocytic syndromes, anti-cytokine and anti-
proliferative therapy (such etoposide, cyclosporine, etc.)
might have been of benefit but given the clinical stability
and the possible deleterious effects of more imunosu-
pression we were not favourable to the use of these
options.
Apart from the aetiology of the hemophagocytic syn-
drome, the strange dynamic of HIV viral load after ART
initiation and the persistence of an “indeterminate”
INNO-LIA HIV testing are all worth of discussion.
Even without treatment, viral load usually declines over
2–6 months in acute HIV infection, concurrent with the
development of HIV-specific immune responses, to ap-
proach a steady state in which viral production and clear-
ance are relatively matched [9].
It is difficult to explain why the viral load firstly in-
creased on therapy and then had an extremely slow de-
cline, having all plausible causes excluded, namely
genotypic viral resistance, phenotypic viral resistance or
infra therapeutic drugs levels. It is possible that this
atypical virological kinetic occurring despite adequate
anti-viral therapy was a result of unchecked macro-
phage/monocyte activation, resulting in rapid/unchecked
HIV virus turnover from these activated cells.
Concerning the peculiar serological findings some could
hypothesize that ART initiation early at diagnosis of acute
HIV infection might have contributed for the persistence
of an “indeterminate” INNO-LIA HIV testing. According
to David Montefiori et al., early ART has a suppressive ef-
fect on the normal antibody response to HIV-1, presum-
ably by limiting the concentration of viral antigens needed
to drive virus-specific B-cell maturation [10, 11].
In our patient however, ART initiation had no signifi-
cant impact on the concentration of virus at an early
stage, meaning that the inhibition of immunological re-
sponse due to the suppressive effect of ART is not plaus-
ible in this case.
For us, the abnormal antibody response can be linked
to the unchecked and disordered B-cell help and activa-
tion that may occur as part of the hemophagocytic
phenomenon. Also, we believe that the patients’ immune
system has somewhat contributed for this unusual pic-
ture. In acute HIV infection, viral decline is concurrent
with the development of specific HIV antibodies. In our
case, even after achieving an almost “undetectable viral
load” and after hemophagocytic syndrome resolution,
HIV confirmatory test was repeatedly “indeterminate”
concluding that the patient did not produce some of the
specific antibodies against HIV.
This hypothesis is further supported by abnormal
levels of specific antibodies against Pneumococcal cap-
sule polysaccharides and tetanus toxoid. It is possible
that the acquired immunodeficiency attributable to HIV
has supervened to an innate disturbance on the patient’s
immune system, which we were unable to identify.
Acute HIV infection treatment decision is made on ex-
trapolation from what is defined for chronic HIV infec-
tion, as clinical trials are scarce.
Case reports like ours might contribute for under-
standing some subtle issues in acute HIV infection,
namely the dynamics of virological and immunological
aspects.
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Additional files
Additional file 1: HIV screening was performed with ARCHITECT HIV
Ag/Ab Combo assay™ (ABBOTT®) for the simultaneous qualitative
detection of HIV-1 p24 antigen and antibodies to HIV-1 (HIV-1 group M
and group O) and HIV-2 and a reactive result (S/CO = 146.5) was ob-
tained. The immunoblot assay- INNO-LIA™ HIV I/II Score (Innogenetics®)
was further performed in the same plasma sample. LiRAS™ (Line Reader
and Analysis Software) was used for automated interpretation and an
indeterminate result was readable (gp41: 3+ and p31: 1+). (DOC 26 kb)
Additional file 2: Genotypic resistance test (ViroSeq™ HIV-1 Genotyping
System v2.0™; ABI Prism 3100 Genetic Analyser™; ViroSeq HIV-1™
Genotyping System Software v2.8; ABBOTT®) and the results interpreted
by the Stanford University HIV Drug Resistance Database (Stanford HIV
db, version 6.0.11, available at http://hivdb.stanford.edu/). (DOC 26 kb)
Additional file 3: Phenotypic resistance testing (PhenoSense GT ®): The
results indicated that the virus (HIV-1 subtype A) was sensitive to all NRTI/
NNRTI and PI drugs, as by the phenotypic as genotypic interpretation (list
of mutations detected: RT – V35T, T39R, E40D, K49R, V80I, Q102K, K122E,
D123S, I42M, A158S, C182S, K173S, Q164K, Q197L, T200A, Q207A, R211S,
E248D, A272P, R277K, T286A, E291D, V292I, P294T, L295M; PR – E35D,
M36I, R41K, I62I/v, H69K, T74T/S, L89M). The combination phenotype/
genotype net assessment showed that the virus was sensitive to all drugs
with a virus replication capacity of 88 %. (DOC 26 kb)
Additional file 4: Three plasma samples from different dates (August,
September and November 2013) were sent to INNOGENETICS reference
laboratory in Belgium for HIV testing (HIV-1 p24 antigen and
immunoblotting). The results were: only one sample (August 2013) gave
a reactive result for the presence of the p24 antigen; all 3 samples gave
an identical result on INNO-LIA HIV Score - indeterminate (with gp41 3+;
p31 +/− or -); confirming the INNO-LIA HIV Score results of our institution.
Based on the INNO-LIA HIV Score results, they concluded that this patient
was not developing common or expected antibody reactivity. (DOC 26 kb)
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